Simcere Pharmaceutical Group to Announce Third Quarter 2012 Financial Results on Thursday, November 15, 2012

NANJING, China, Nov. 1, 2012 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2012 on Thursday, November 15, 2012, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, November 15, at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

International toll:

+65.6723.9381

United States toll-free:

+1.866.519.4004

United States toll:

+1.718.354.1231

China Domestic toll:

800.819.0121

China Domestic mobile toll:

400.620.8038

Hong Kong toll:

+852.2475.0994

Please ask to be connected to Q3 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 57347315.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free:

+1.866.214.5335

United States toll:

+1.718.354.1232

The passcode for replay participants is 57347315. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:


Email: ir@simcere.com




In Nanjing:

Jie Liu D'Elia

Vice President

Simcere Pharmaceutical Group

Tel: 86-25-8556-6666*8857

 

In Beijing:

Yue Yu

Brunswick Group

Tel: 86-10-5960-8600

In the United States:

Carly Westerman

Brunswick Group

Tel: 1-212-333-3810

 


In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: 852-3512-5000 

SOURCE Simcere Pharmaceutical Group



RELATED LINKS
http://www.simcere.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.